Ballantyne Christie M, Manku Mehar S, Bays Harold E, Philip Sephy, Granowitz Craig, Doyle Ralph T, Juliano Rebecca A
Department of Medicine, Baylor College of Medicine and the Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Amarin Pharma Inc, Bedminster, NJ, USA.
Cardiol Ther. 2019 Jun;8(1):79-90. doi: 10.1007/s40119-019-0131-8. Epub 2019 Feb 20.
Fatty acid content in plasma and red blood cells (RBCs) may provide insight into potential physiologic benefits of omega-3 fatty acids. Icosapent ethyl is a pure prescription form of eicosapentaenoic acid (EPA) ethyl ester approved by the US Food and Drug Administration at a dose of 4 g/day as an adjunct to diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dl) hypertriglyceridemia.
This was a prespecified exploratory subset analysis of the ANCHOR study, which randomized 702 statin-treated patients at increased cardiovascular risk with triglycerides 200-499 mg/dl and controlled low-density lipoprotein cholesterol (40-99 mg/dl). This analysis examined effects of icosapent ethyl 4 g/day versus placebo on fatty acid levels in plasma and RBCs using a gas chromatograph assay method with flame ionization detector.
In plasma, treatment with icosapent ethyl 4 g/day resulted in significant increases versus placebo in the mean concentrations of EPA (+ 635%; P < 0.0001) and its metabolite, docosapentaenoic acid n-3 (+ 143%; P < 0.0001) with no significant change in docosahexaenoic acid. Treatment with icosapent ethyl 4 g/day versus placebo also resulted in significant decreases in the omega-6 fatty acids linoleic acid (- 25%) and arachidonic acid (AA; - 31%), as well as the AA/EPA ratio (- 91%). Icosapent ethyl 4 g/day also decreased the omega-9 fatty acid oleic acid (- 29%) and the saturated fatty acids palmitic acid (- 23%) and stearic acid (- 16%) (all P < 0.0001). Results were similar for RBCs.
Icosapent ethyl 4 g/day significantly increased EPA and produced other potentially beneficial shifts in fatty acids in plasma and RBCs versus placebo.
ClinicalTrials.gov Identifier, NCT01047501 FUNDING: Amarin Pharma Inc. Plain language summary available for this article.
血浆和红细胞（RBC）中的脂肪酸含量可能有助于深入了解ω-3脂肪酸的潜在生理益处。二十碳五烯酸乙酯是一种纯处方形式的二十碳五烯酸（EPA）乙酯，已获美国食品药品监督管理局批准，剂量为4克/天，作为饮食的辅助手段，用于降低重度（≥500毫克/分升）高甘油三酯血症成年患者的甘油三酯水平。
这是对ANCHOR研究的一项预先指定的探索性子集分析，该研究将702名心血管疾病风险增加、甘油三酯水平为200 - 499毫克/分升且低密度脂蛋白胆固醇得到控制（40 - 99毫克/分升）的他汀类药物治疗患者随机分组。该分析采用带有火焰离子化检测器的气相色谱分析法，研究每天4克二十碳五烯酸乙酯与安慰剂相比对血浆和红细胞中脂肪酸水平的影响。
在血浆中，与安慰剂相比，每天服用4克二十碳五烯酸乙酯导致EPA的平均浓度显著升高（+635%；P < 0.0001）及其代谢物二十二碳五烯酸n - 3的平均浓度显著升高（+143%；P < 0.0001），而二十二碳六烯酸无显著变化。与安慰剂相比，每天服用4克二十碳五烯酸乙酯还导致ω-6脂肪酸亚油酸（-25%）和花生四烯酸（AA；-31%）以及AA/EPA比值（-91%）显著降低。每天4克二十碳五烯酸乙酯还降低了ω-9脂肪酸油酸（-29%）以及饱和脂肪酸棕榈酸（-23%）和硬脂酸（-16%）（所有P < 0.0001）。红细胞的结果相似。
与安慰剂相比，每天4克二十碳五烯酸乙酯显著增加了EPA，并在血浆和红细胞的脂肪酸方面产生了其他潜在有益的变化。
ClinicalTrials.gov标识符，NCT01047501 资助：Amarin制药公司 本文提供通俗易懂的摘要。
